Regenerative Focus Targeted outreach highlighting Celavie’s focus on undifferentiated, allogeneic pluripotent stem cell therapies for CNS disorders, presenting opportunities for contract development, manufacturing, and research collaborations in regenerative medicine.

IP Strength Leverage Celavie’s robust IP portfolio (18 issued patents) to propose co-development or licensing discussions around proprietary stem cell platforms and differentiation-free approaches that could extend market reach or create defensible partnerships.

Veterinary Synergy Explore cross-portfolio value by expanding Celavet technologies into veterinary CNS and serious disease applications, offering scalable biologics manufacturing, dosing strategies, and regulatory-compliant solutions for animal health customers.

Early-Stage Growth With a small team and a revenue range indicative of a developing company, present scalable software, cloud, and data-management solutions, along with CRO/CMO partnerships to accelerate research timelines and cost control.

Strategic Partnerships Position Celavie for collaborations with mid-to-large players in life sciences and contract services by offering integrated platforms, IP-enabled programs, and manufacturing readiness services that align with their growth and regulatory milestones.